1-3 of 3
Tim Clackson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D. Wardwell, David Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei-Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana Narasimhan, Frank Wang, Juan Miret, Xiaotian Zhu, Tim Clackson, David Dalgarno, William C. Shakespeare, Victor M. Rivera
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5527–5538.
https://doi.org/10.1158/1078-0432.CCR-16-0569
Published: 14 November 2016
View article titled, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Open the PDF for The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (22): 5745–5755.
https://doi.org/10.1158/1078-0432.CCR-14-1397
Published: 13 November 2014
View article titled, Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Open the PDF for Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients in another window
Includes: Supplementary data
Journal Articles

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

Thomas O'Hare, Michael W.N. Deininger, Christopher A. Eide, Tim Clackson, Brian J. Druker
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 212–221.
https://doi.org/10.1158/1078-0432.CCR-09-3314
Published: 16 January 2011
View article titled, Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Open the PDF for Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia in another window